###begin article-title 0
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 101 102 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 102 104 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">S&#8414;</xref>
###xml 104 104 101 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2"/>
MafA and MafB Regulate Pdx1 Transcription through the Area II Control Region in Pancreatic beta Cells*Sâƒž
###end article-title 0
###begin p 1
Present address: Sarah W. Stedman Nutrition and Metabolism Center and Department of Pharmacology, Duke University Medical Center, Durham, NC.
###end p 1
###begin p 2
Present address: Department of Pathology, Vanderbilt Medical School, Nashville, TN.
###end p 2
###begin p 3
Present address: Program for Developmental Biology & Stem Cell Research, University of Lund, Sweden.
###end p 3
###begin p 4
###xml 92 119 92 119 <email xmlns:xlink="http://www.w3.org/1999/xlink">Roland.Stein@Vanderbilt.edu</email>
 To whom correspondence should be addressed. Tel.: 615-322-7026; Fax: 615-322-7236; E-mail: Roland.Stein@Vanderbilt.edu. 
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 5
###begin p 6
 applies to Author Choice Articles
###end p 6
###begin p 7
###xml 0 1 0 1 <underline xmlns:xlink="http://www.w3.org/1999/xlink">P</underline>
###xml 11 12 11 12 <underline xmlns:xlink="http://www.w3.org/1999/xlink">d</underline>
###xml 27 28 27 28 <underline xmlns:xlink="http://www.w3.org/1999/xlink">x</underline>
###xml 36 37 36 37 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 227 234 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 388 392 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 890 894 878 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 954 955 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 974 978 962 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 978 981 966 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1065 1069 1050 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1150 1154 1135 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
###xml 982 986 <span type="species:ncbi:10090">mice</span>
Pancreatic-duodenal homeobox factor-1 (Pdx1) is highly enriched in islet beta cells and integral to proper cell development and adult function. Of the four conserved 5'-flanking sequence blocks that contribute to transcription in vivo, Area II (mouse base pairs -2153/-1923) represents the only mammalian specific control domain. Here we demonstrate that regulation of beta-cell-enriched Pdx1 expression by the MafA and MafB transcription factors is exclusively through Area II. Thus, these factors were found to specifically activate through Area II in cell line transfection-based assays, and MafA, which is uniquely expressed in adult islet beta cells was only bound to this region in quantitative chromatin immunoprecipitation studies. MafA and MafB are produced in beta cells during development and were both bound to Area II at embryonic day 18.5. Expression of a transgene driven by Pdx1 Areas I and II was also severely compromised during insulin+ cell formation in MafB-/- mice, consistent with the importance of this large Maf in beta-cell production and Pdx1 expression. These findings illustrate the significance of large Maf proteins to Pdx1 expression in beta cells, and in particular MafB during pancreatic development.
###end p 7
###begin p 8
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 97 86 97 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">P01 DK42502</grant-num>
###xml 100 107 100 107 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">DK50203</grant-num>
###xml 123 138 123 138 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">5T32 DK07563-20</grant-num>
###xml 138 164 138 164 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">METP postdoctoral training</grant-sponsor>
###xml 221 250 221 250 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">American Diabetes Association</grant-sponsor>
###xml 252 263 252 263 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">7-04-RA-116</grant-num>
###xml 283 320 283 320 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Juvenile Diabetes Research Foundation</grant-sponsor>
###xml 344 353 344 353 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">10-2006-5</grant-num>
###xml 448 507 448 507 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Vanderbilt University Diabetes Research and Training Center</grant-sponsor>
###xml 537 548 537 548 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">P60 DK20593</grant-num>
###xml 692 705 692 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants P01 DK42502 & DK50203 (to R. S.) and 5T32 DK07563-20METP postdoctoral training (to A. V.). This work was also supported in part by the American Diabetes Association (7-04-RA-116, to R. S.) and the Juvenile Diabetes Research Foundation (Advanced Postdoctoral 10-2006-5, to I. A.). Partial support was also provided to the Molecular Biology Core Laboratory by the Vanderbilt University Diabetes Research and Training Center (Public Health Service Grant P60 DK20593). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
The on-line version of this article (available at ) contains supplemental Fig. S1 and Tables S1 and S2.
###end p 9
###begin p 10
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 10
###begin p 11
###xml 347 348 338 339 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 358 359 349 350 <underline xmlns:xlink="http://www.w3.org/1999/xlink">d</underline>
###xml 374 375 365 366 <underline xmlns:xlink="http://www.w3.org/1999/xlink">x</underline>
###xml 384 385 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn7">5</xref>
###xml 506 507 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 509 510 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 669 670 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 671 672 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 804 805 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 807 808 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 876 877 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 979 980 961 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 982 983 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 986 990 968 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1082 1083 1064 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1158 1159 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 1161 1162 1140 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 395 401 <span type="species:ncbi:9606">humans</span>
###xml 616 622 <span type="species:ncbi:9606">humans</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 1074 1080 <span type="species:ncbi:9606">humans</span>
Much effort is currently being directed to define the biochemical pathways essential to islet beta-cell formation, with the hope that such insight will aid in the development of treatment strategies aimed at reducing beta-cell dysfunction in diabetic patients. A transcription factor that is critical to both beta-cell development and function is pancreatic-duodenal homeobox-1 (Pdx1,5 IPF-1 in humans), the first pancreas-enriched gene product expressed in budding epithelium at embryonic day 8.5 (E8.5) (1, 2). Pdx1 is produced in early pancreatic endocrine, exocrine, and ductal progenitors, and complete loss in humans and mice results in an apancreatic phenotype (3-5). Later in development, islet beta cells can be distinguished from pancreatic exocrine and ductal cells by their high Pdx1 levels (1, 2). In mature pancreas, Pdx1 is principally localized to beta cells (1), with specific removal leading to a severe diabetic phenotype due to beta-cell dysfunction in mice (6, 7). Pdx1 is also one of few genes associated with an autosomal dominant form of diabetes in humans (5) and is viewed as a master regulator of beta-cell formation and function (8, 9).
###end p 11
###begin p 12
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 397 404 397 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 733 737 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 948 950 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 978 982 978 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1113 1120 1110 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1122 1124 1119 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
Endogenous Pdx1 expression is predominately controlled by four conserved 5'-flanking sequence domains, referred to as Area I (mouse AI, base pairs (bp) -2761/-2457), AII (bp -2153/-1923), AIII (bp -1879/-1600), and AIV (bp -6529/-6047) (10-12). AI-III mediates pancreas-specific expression, as early targeted removal of these regions from the endogenous gene profoundly reduces pancreas formation in vivo, while leaving Pdx1 expression in the stomach and duodenum intact (13). Several transgenic reporter lines encompassing AI, AII, and AIII have been developed to more precisely define their roles in pancreatic expression. Interactions between AIII and AI/II have been shown to be necessary in the early and broad transcription of Pdx1 in acinar, endocrine, and ductal progenitors (14). In contrast, AI and AII cooperate to selectively induce high Pdx1 expression in the insulin+ cells produced after E13.5 that populate the adult islet (10, 15, 16). Notably, AII is the only Pdx1 control region unique to mammals and capable of independently directing transgenic expression to (a fraction of) islet beta cells in vivo (17).
###end p 12
###begin p 13
###xml 39 43 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 171 174 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 273 275 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 277 279 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 280 282 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 457 461 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 515 517 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 518 520 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 904 911 889 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1037 1041 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 1041 1044 1023 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1163 1167 1145 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
Islet beta-cell-enriched expression of Pdx1 appears to be principally regulated by AII, and several key islet transcription factors bind to and activate through conserved cis-acting elements in this mammalian-specific control region, including FoxA2, Pax6, MafA, and MafB (11, 15-19). These closely related large Maf proteins are both expressed in beta cells during development, with MafA found uniquely in adult islet beta cells and only MafB compromising Pdx1 expression andbeta-cell formation in knock-out mice (20-22). Here we first identified a new conserved MafA and/or MafB binding site in AII. Chromatin immunoprecipitation (ChIP) analysis then illustrated that MafA binding within AII was highly enriched over AI, AIII, and AIV in islet beta cell lines, while transfection-based reporter assays showed that the MafA/MafB binding elements contributed to activation. Both MafA and MafB were bound in vivo to Area II in E18.5 pancreata, and AI/AII-driven transgene activity was dramatically reduced during beta-cell development in MafB-/- mice. Collectively, these data support an essential role for MafA and MafB specifically in AII-mediated activation of Pdx1 transcription, and highlight the significance of MafB regulation in developing beta cells.
###end p 13
###begin title 14
EXPERIMENTAL PROCEDURES
###end title 14
###begin p 15
###xml 0 43 0 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electrophoretic Mobility Shift Assay (EMSA)</italic>
###xml 142 143 139 140 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 201 202 198 199 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 228 229 225 226 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 370 371 367 368 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 392 393 389 390 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 403 404 400 401 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 414 415 411 412 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 425 426 422 423 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 446 447 443 444 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 482 483 479 480 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 509 510 506 507 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 658 660 651 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 760 762 751 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 849 850 839 840 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 874 875 864 865 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 885 886 875 876 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 906 907 896 897 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1338 1339 1328 1329 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1351 1352 1341 1342 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1365 1366 1355 1356 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Electrophoretic Mobility Shift Assay (EMSA)-betaTC3, MIN6, HeLa, and NIH3T3 cell nuclear extracts (NE) were prepared using lysis buffer (100 mm Tris-HCl, pH 8.0, 0.5% Igepal CA-630 (Sigma-Aldrich), 2 mm sodium orthovanadate, 2 mm sodium fluoride, and protease inhibitor mixture (Roche Applied Science)), followed by pellet resuspension in nuclear extraction buffer (20 mm Hepes, pH 7.9, 400 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1 mm dithiothreitol, 1 mm phenylmethylsulfonyl fluoride, 2 mm sodium orthovanadate, 2 mm sodium fluoride, and protease inhibitor mixture). The Area II double-stranded oligonucleotide probes were polynucleotide kinase-labeled with [gamma32P]dATP. Reactions (20 mul, total volume) were conducted with 10 mug of nuclear extract, 0.4 pmol of 32P probe, and 1 mug of poly(dGdC) at room temperature for 10 min in binding buffer (20 mm Tris-HCl, pH 7.4, 200 mm NaCl, 4 mm dithiothreitol, 2 mm EDTA, and 20% glycerol). The conditions for the competition analyses were the same, except that a 10-100-fold excess of the unlabeled specific competitor DNA was included. To identify protein-DNA complexes, MafA (Bethyl Labs, Montgomery, TX), MafB (Bethyl Labs), or Pax6 (Covance, Dedham, MA) antibody was added to the indicated binding reactions. Samples were resolved on a 6% nondenaturing polyacrylamide gel in TGE buffer (50 mm Tris, 380 mm glycine, 2 mm EDTA, pH 8.5) before drying and autoradiography. The commercially generated (IDT, Coralville, IA) probe and competitor sequences are shown in supplemental Table S1.
###end p 15
###begin p 16
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Transfection Construct</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 785 786 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 779 786 779 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 1012 1022 1012 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1309 1311 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 343 348 <span type="species:ncbi:10090">mouse</span>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 491 496 <span type="species:ncbi:10090">mouse</span>
###xml 1012 1022 <span type="species:ncbi:7227">Drosophila</span>
###xml 1110 1115 <span type="species:ncbi:10090">mouse</span>
Transfection Construct-Pdx1 reporter constructs were generated using mouse and human sequences, cloned directly upstream of the herpes simplex virus thymidine kinase (TK) minimal promoter in a chloramphenicol acetyltransferase (CAT) expression vector, pTK(An):CAT (23). The previously generated Pdx1:pTK constructs are as follows: PstBst:pTK (mouse -2917/-1918 bp, (16)); huAII:pTK (human -2141/-1890bp, (17)); mAI:pTK (mouse -2761/-2457 (12)); mAII: pTK (mouse -2153/-1923 (12)); mAIV:pTK (mouse -6529/-6010 (12)); and mAI/II:pTK ((AI) 2759/-2439 and (AII) -2200/-1923(15)). The Pdx1:pTK mutants were generated using the QuikChange mutagenesis kit (Stratagene): PstBst: pTK at B2 (-2126/-2115) (17), B4/5 (-2101/-2086, (18), and B2-5 (-2126/2086); huAII:pTK at B2-TGC and -CAC (Fig. 2D); mAI/II:pTK TGC mutations at 5' (-2180/-2178), B2 (-2120/-2118), B4 (-2098/-2096), and B13 (-2009/-2007). MafA and MafB expression constructs were described previously (24). EnMafB:pcDNA3.1 expresses a fusion protein of the Drosophila Engrailed (En) N-terminal repressor domain (coding sequence for amino acids 1-298) and mouse MafB C-terminal DNA binding domain (coding sequence for amino acids 82-324). These sequences were cloned into pcDNA3.1 (Invitrogen) along with a DNA fragment encoding an IRES and nuclear EGFP (25). All construct sequences were confirmed by restriction enzyme digestion and partial sequence analysis.
###end p 16
###begin p 17
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cell Transfections</italic>
###xml 326 330 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 455 456 452 453 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 571 573 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 584 586 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 788 789 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 87 90 <span type="species:ncbi:10116">rat</span>
###xml 171 176 <span type="species:ncbi:9796">horse</span>
###xml 189 193 <span type="species:ncbi:9913">calf</span>
###xml 215 233 <span type="species:ncbi:11886">Rous sarcoma virus</span>
Cell Transfections-Monolayer cultures of mouse pancreatic insulinoma betaTC3 cells and rat kidney KNRK cells were grown in Dulbecco modified Eagle's medium containing 17% horse serum or 5% calf serum, respectively. Rous sarcoma virus enhancer-driven firefly luciferase (pRSV:LUC) was cotransfected as an internal control with Pdx1:pTK using Lipofectamine (Invitrogen, Carlsbad, CA). Extracts were prepared 40-48 h after transfection in lysis buffer (100 mm Tris-HCl, pH 8.0, 0.5% Igepal CA-630, and protease inhibitor mixture (Roche Applied Science) and assayed for CAT (26) and LUC (27) activity. Transfections were conducted with at least two different experimental plasmid preparations. Statistical analysis was performed by one-way analysis of variance followed by Fisher's PSLD, and p < 0.05 was considered significant.
###end p 17
###begin p 18
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ChIP Assays</italic>
###xml 187 189 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 847 848 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 853 861 832 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1/slope</sup>
###xml 912 916 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 986 991 965 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 1033 1035 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 1064 1068 1043 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1333 1337 1312 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1350 1355 1329 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 1420 1422 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
###xml 327 333 <span type="species:ncbi:9986">rabbit</span>
###xml 366 372 <span type="species:ncbi:9986">rabbit</span>
###xml 1162 1167 <span type="species:ncbi:10090">mouse</span>
ChIP Assays-betaTC3 cells and disrupted mouse E18.5 pancreata were formaldehyde cross-linked, and the sonicated protein-DNA complexes were isolated under conditions described previously (19). 100 mug of cross-linked betaTC3 DNA or 5 mug of cross-linked E18.5 pancreata DNA were incubated with 10 mug or 5 mug, respectively, of rabbit anti-MafA, anti-MafB, or normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 degreesC, and the antibody/protein/DNA complexes were isolated with protein A-agarose blocked with salmon sperm DNA (Upstate, Charlottesville, VA). Real time PCR analysis was performed on the purified, immunoprecipitated betaTC3 DNA using SyBr green PCR master mix (Applied Biosciences) and the ABI Prism 7000. Input DNA was utilized to generate a standard curve, and only reactions with 100 +/- 20% efficiency (E = 10-1/slope) were included in the analysis. The enrichment of Pdx1 control sequences per sample was calculated relative to the inactive PEPCK promoter by employing the Pfaffl method (28) and the enrichment of each Pdx1 control sequence was compared by one-way analysis of variance followed by Fisher's PSLD. The mouse primer sets were generated with the ABI software and provided in supplemental Table S2. The purified immunoprecipitated E18.5 pancreata DNA was analyzed by PCR with Pdx1 Area II and PEPCK transcriptional control region primers as described previously (19). Amplified products were resolved on a 1.4% agarose gel in Tris acetate/EDTA buffer containing ethidium bromide.
###end p 18
###begin p 19
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemistry</italic>
###xml 35 41 35 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/AII</sup>
###xml 31 50 31 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/AII</sup> hsp-LacZ</italic>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 179 185 179 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/AII</sup>
###xml 174 194 174 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1<sup>AI/AII</sup> hsp-LacZ</italic>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 1201 1202 1169 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1423 1424 1388 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 549 555 <span type="species:ncbi:9986">rabbit</span>
###xml 608 618 <span type="species:ncbi:10141">guinea pig</span>
###xml 679 683 <span type="species:ncbi:9925">goat</span>
###xml 821 827 <span type="species:ncbi:9986">rabbit</span>
###xml 1006 1016 <span type="species:ncbi:10141">guinea pig</span>
###xml 1031 1035 <span type="species:ncbi:9925">goat</span>
Immunohistochemistry-The mouse Pdx1AI/AII hsp-LacZ transgenic line (15) was crossed into the MafB+/- line (29) to generate wild-type and MafB-/- littermates that contain the Pdx-1AI/AII hsp-LacZ transgene. The day of vaginal plug discovery was designated E0.5 and tissue was harvested on E18.5, as MafB-/- mice die at birth because of central apnea (29). Abdominal organs and pancreata were fixed, dehydrated, embedded in paraffin, and 6-mum serial sections were mounted on glass slides for immunohistochemical analysis. The primary antibodies were rabbit alpha-beta galactosidase (1:500; Molecular Probes), guinea pig alpha-insulin (1:2000, Linco Research, ST Charles, MO), and goat alpha-Pdx1 (1:10,000, Chris Wright, Vanderbilt University Medical School). The beta-gal signal was enhanced with biotin-conjugated alpha-rabbit (1:500, Jackson ImmunoResearch, West Grove, PA) and Cy5-conjugated streptavidin (1:1000 Jackson ImmunoResearch). Fluorescence-conjugated secondary antibodies used were Cy3-alpha-guinea pig and Cy2-alpha-goat (1:500, Jackson ImmunoResearch). Fluorescent images were captured with a Zeiss LSM 510 confocal microscope using an optical depth of 1 mum. The percentage of insulin+ cells co-staining for beta-galactosidase was determined by counting cells in at least 20 random fields throughout the pancreas, and mean differences were tested for statistical significance with the Student's two tailed t test.
###end p 19
###begin p 20
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 9 58 9 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and Pax6 bind to the AII B2 element <italic>in vitro</italic></bold>
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 161 183 161 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined nucleotides</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 358 362 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min6</italic>
###xml 371 374 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC3</italic>
###xml 395 401 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NIH3T3</italic>
###xml 575 583 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 657 663 637 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 666 667 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 851 855 828 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 971 972 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 1258 9 1235 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21"><bold>MafA and Pax6 bind to the AII B2 element <italic>in vitro</italic></bold>. <italic>A</italic>, sequence identity within the B2, B4, and B5 region of <italic>Pdx1</italic> between various mammalian species. The <italic>underlined nucleotides</italic> represent differences with the two reported large Maf consensus sequences (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref47">47</xref>). <italic>B</italic>, sequences spanning mouse and human B2 were used in gel shift binding assays with &#946;-(<italic>Min6</italic> and &#946;<italic>TC3</italic>) and non-&#946;-cell (<italic>NIH3T3</italic>) nuclear extract. Three &#946;-cell-specific B2 complexes were detected, with the upper two supershifted by &#945;-MafA and the lower disrupted with &#945;-Pax6 antibodies. The <italic>asterisk</italic> denotes a nonspecific complex, as concluded from B2 mutant analysis (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>). <italic>C</italic>, specificity of MafA-DNA complex formation in &#946;TC3 extracts was determined by competition with a 10&#8211;100-fold molar excess of unlabeled probe and large Maf binding competitors, the <italic>Pdx1</italic> AII B4/5 element and insulin C1 element. Notably, mB2 competes as effectively as mB4/5 and InsC1 for MafA binding. <italic>D</italic>, MafB-mB2 complex in MafB-transfected HeLa cell extracts had similar binding properties to MafA in competitions with 10&#8211;100-fold molar excess of the probe and large Maf binding competitors. The anti-MafB antibody supershift illustrates the location of the MafB complex formed with mB2.</p>
###xml 9 1258 9 1235 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21"><bold>MafA and Pax6 bind to the AII B2 element <italic>in vitro</italic></bold>. <italic>A</italic>, sequence identity within the B2, B4, and B5 region of <italic>Pdx1</italic> between various mammalian species. The <italic>underlined nucleotides</italic> represent differences with the two reported large Maf consensus sequences (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref47">47</xref>). <italic>B</italic>, sequences spanning mouse and human B2 were used in gel shift binding assays with &#946;-(<italic>Min6</italic> and &#946;<italic>TC3</italic>) and non-&#946;-cell (<italic>NIH3T3</italic>) nuclear extract. Three &#946;-cell-specific B2 complexes were detected, with the upper two supershifted by &#945;-MafA and the lower disrupted with &#945;-Pax6 antibodies. The <italic>asterisk</italic> denotes a nonspecific complex, as concluded from B2 mutant analysis (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>). <italic>C</italic>, specificity of MafA-DNA complex formation in &#946;TC3 extracts was determined by competition with a 10&#8211;100-fold molar excess of unlabeled probe and large Maf binding competitors, the <italic>Pdx1</italic> AII B4/5 element and insulin C1 element. Notably, mB2 competes as effectively as mB4/5 and InsC1 for MafA binding. <italic>D</italic>, MafB-mB2 complex in MafB-transfected HeLa cell extracts had similar binding properties to MafA in competitions with 10&#8211;100-fold molar excess of the probe and large Maf binding competitors. The anti-MafB antibody supershift illustrates the location of the MafB complex formed with mB2.</p></caption>
###xml 1258 1258 1235 1235 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570001"/>
###xml 0 1258 0 1235 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="21"><bold>MafA and Pax6 bind to the AII B2 element <italic>in vitro</italic></bold>. <italic>A</italic>, sequence identity within the B2, B4, and B5 region of <italic>Pdx1</italic> between various mammalian species. The <italic>underlined nucleotides</italic> represent differences with the two reported large Maf consensus sequences (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref47">47</xref>). <italic>B</italic>, sequences spanning mouse and human B2 were used in gel shift binding assays with &#946;-(<italic>Min6</italic> and &#946;<italic>TC3</italic>) and non-&#946;-cell (<italic>NIH3T3</italic>) nuclear extract. Three &#946;-cell-specific B2 complexes were detected, with the upper two supershifted by &#945;-MafA and the lower disrupted with &#945;-Pax6 antibodies. The <italic>asterisk</italic> denotes a nonspecific complex, as concluded from B2 mutant analysis (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>). <italic>C</italic>, specificity of MafA-DNA complex formation in &#946;TC3 extracts was determined by competition with a 10&#8211;100-fold molar excess of unlabeled probe and large Maf binding competitors, the <italic>Pdx1</italic> AII B4/5 element and insulin C1 element. Notably, mB2 competes as effectively as mB4/5 and InsC1 for MafA binding. <italic>D</italic>, MafB-mB2 complex in MafB-transfected HeLa cell extracts had similar binding properties to MafA in competitions with 10&#8211;100-fold molar excess of the probe and large Maf binding competitors. The anti-MafB antibody supershift illustrates the location of the MafB complex formed with mB2.</p></caption><graphic xlink:href="zbc0340845570001"/></fig>
###xml 290 295 <span type="species:ncbi:10090">mouse</span>
###xml 300 305 <span type="species:ncbi:9606">human</span>
FIGURE 1.MafA and Pax6 bind to the AII B2 element in vitro. A, sequence identity within the B2, B4, and B5 region of Pdx1 between various mammalian species. The underlined nucleotides represent differences with the two reported large Maf consensus sequences (30, 47). B, sequences spanning mouse and human B2 were used in gel shift binding assays with beta-(Min6 and betaTC3) and non-beta-cell (NIH3T3) nuclear extract. Three beta-cell-specific B2 complexes were detected, with the upper two supershifted by alpha-MafA and the lower disrupted with alpha-Pax6 antibodies. The asterisk denotes a nonspecific complex, as concluded from B2 mutant analysis (see Fig. 2). C, specificity of MafA-DNA complex formation in betaTC3 extracts was determined by competition with a 10-100-fold molar excess of unlabeled probe and large Maf binding competitors, the Pdx1 AII B4/5 element and insulin C1 element. Notably, mB2 competes as effectively as mB4/5 and InsC1 for MafA binding. D, MafB-mB2 complex in MafB-transfected HeLa cell extracts had similar binding properties to MafA in competitions with 10-100-fold molar excess of the probe and large Maf binding competitors. The anti-MafB antibody supershift illustrates the location of the MafB complex formed with mB2.
###end p 20
###begin p 21
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and Pax6 bind to the AII B2 element <italic>in vitro</italic></bold>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 152 174 152 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined nucleotides</italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 349 353 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min6</italic>
###xml 362 365 356 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC3</italic>
###xml 386 392 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NIH3T3</italic>
###xml 566 574 546 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 648 654 628 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 657 658 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 842 846 819 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 962 963 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
###xml 291 296 <span type="species:ncbi:9606">human</span>
MafA and Pax6 bind to the AII B2 element in vitro. A, sequence identity within the B2, B4, and B5 region of Pdx1 between various mammalian species. The underlined nucleotides represent differences with the two reported large Maf consensus sequences (30, 47). B, sequences spanning mouse and human B2 were used in gel shift binding assays with beta-(Min6 and betaTC3) and non-beta-cell (NIH3T3) nuclear extract. Three beta-cell-specific B2 complexes were detected, with the upper two supershifted by alpha-MafA and the lower disrupted with alpha-Pax6 antibodies. The asterisk denotes a nonspecific complex, as concluded from B2 mutant analysis (see Fig. 2). C, specificity of MafA-DNA complex formation in betaTC3 extracts was determined by competition with a 10-100-fold molar excess of unlabeled probe and large Maf binding competitors, the Pdx1 AII B4/5 element and insulin C1 element. Notably, mB2 competes as effectively as mB4/5 and InsC1 for MafA binding. D, MafB-mB2 complex in MafB-transfected HeLa cell extracts had similar binding properties to MafA in competitions with 10-100-fold molar excess of the probe and large Maf binding competitors. The anti-MafB antibody supershift illustrates the location of the MafB complex formed with mB2.
###end p 21
###begin title 22
RESULTS
###end title 22
###begin p 23
###xml 0 54 0 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The AII B2 Element Binds MafA, MafB, and Pax6 in Vitro</italic>
###xml 174 176 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 347 349 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 360 361 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 354 361 351 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 567 571 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIN6</italic>
###xml 580 583 571 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC3</italic>
###xml 587 593 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NIH3T3</italic>
###xml 603 604 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 597 604 588 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 775 777 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 779 781 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 939 940 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 933 940 921 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1114 1123 1102 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide</italic>
###xml 1159 1161 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 1163 1165 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 1181 1183 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1192 1193 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1186 1193 1174 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 1240 1241 1228 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1234 1241 1222 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1370 1371 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1364 1371 1352 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 483 488 <span type="species:ncbi:10090">mouse</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
The AII B2 Element Binds MafA, MafB, and Pax6 in Vitro-Mutation analysis of conserved AII sequences revealed several activator sites in beta cell line-based reporter assays (17). Upon examination of these sequences, Block 2 (B2, bp -2124/-2113 in mice) was found to have high identity with the recently described large Maf binding consensus (Ref. 30 and Fig. 1A). Three bands were specifically detected in gel shift experiments performed with beta-cell nuclear extracts using either mouse or human B2 probes, with the top two supershifted with MafA antibody (compare MIN6 and betaTC3 to NIH3T3 in Fig. 1B). Antibody screening studies demonstrated that the other band contains the Pax6 transcription factor, another activator of islet cell development and beta-cell function (31, 32). However, the interaction between Pax6 and B2 appears to be weak, because the Pax6-DNA complex was disrupted by a supershift competent Pax6 antibody (Fig. 1B), and only a very small amount of Pax6 was bound when compared with a Pax6 consensus site probe (data not shown). In contrast, B2 had high affinity for MafA as judged using bona fide large Maf competitors, Insulin C1 (24, 33) and AII B4/5 (17) (Fig. 1C). (AII B4/5 resides just 14 bp from B2 (Fig. 1A)). Using the same large Maf competitors, MafB was also observed to bind the B2 element with the same specificity as MafA (Fig. 1D). These data identify the B2 element of Area II as large Maf and Pax6 binding sites in EMSA, albeit Pax6 relatively poorly.
###end p 23
###begin p 24
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Only MafA or MafB Stimulate B2 Activity</italic>
###xml 237 243 237 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 437 440 437 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B&#8211;D</italic>
###xml 429 440 429 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>B&#8211;D</italic></xref>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGCmt</italic>
###xml 607 610 607 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B&#8211;D</italic>
###xml 599 610 599 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>B&#8211;D</italic></xref>
###xml 616 621 616 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CACmt</italic>
Only MafA or MafB Stimulate B2 Activity-Gel shift assays were performed with a series of B2 mutants to more precisely localize large Maf and Pax6 protein binding. Two unique 3-bp mutants were identified that distinguished their binding (Fig. 2). Hence, changing the TGC core in the large Maf consensus completely eliminates MafA and MafB binding to B2 without impacting Pax6 association in competition and direct binding assays (Fig. 2, B-D, see TGCmt). In contrast, mutation of individual base pairs outside of the large Maf consensus disrupted Pax6 binding without impairing MafA or MafB binding (Fig. 2, B-D, see CACmt).
###end p 24
###begin p 25
###xml 342 343 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 336 343 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 447 451 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 823 824 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 817 824 811 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 71 76 <span type="species:ncbi:9606">human</span>
The effect of the large Maf and Pax6 distinguishing mutations in B2 on human AII-driven activity was analyzed in beta cell line transfection assays, a context wherein only MafA and Pax6 are expressed. Selectively eliminating MafA binding in betaTC3 cells reduces AII activity, while the Pax6 binding mutant slightly increases activity (Fig. 2E). It is possible that AII B2-CAC mutant activity was potentiated due to either removal of a repressor (i.e. Pax6) or enhanced MafA activator binding. We favor the latter, as Pax6 actually binds very weakly to this site in relation to MafA/B in gel shift assays, and there is no precedence for this factor acting in a repressive manner. In addition, MafA binding was increased in the Pax6 binding mutant, as observed in concentration-dependent competition gel shift assays (Fig. 2B).
###end p 25
###begin p 26
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 60 9 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA stimulates B2-mediated activity, but not Pax6.</bold>
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 174 187 174 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined. B</italic>
###xml 440 441 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 848 849 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1172 1173 1158 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1432 1433 1415 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1442 1443 1425 1426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1445 1446 1428 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1455 1461 1438 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 1473 9 1456 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27"><bold>MafA stimulates B2-mediated activity, but not Pax6.</bold><italic>A</italic>, shown is the relationship of the TGC and CAC mutations to the large Maf consensus. The mutated nucleotides are <italic>underlined. B</italic>, competition assays (10&#8211;100-fold excess) were performed to analyze for MafA and Pax6 binding to the TGC and CAC mutants of B2. The TGCmt specifically competes for Pax6 binding in&#946;TC3 nuclear extracts, while only MafA binding is lost with the CACmt. <italic>C</italic>, nuclear extracts from MafB-transfected Hela cells were used in competition assays (10&#8211;100-fold excess) to analyze for MafB binding to the TGC and CAC mutants of B2. As observed with MafA, the TGC mutation does not compete for MafB binding while the CAC mutant effectively competes for MafB. A control lane with vector-transfected Hela nuclear extract is included to demonstrate the MafB-DNA complex band. <italic>D</italic>, binding assays were conducted with wild-type and mutant B2 probes to further illustrate the difference in TGCmt and CACmt binding to Pax6 and MafA, respectively. The location of MafA and Pax6 complexes were illustrated by addition of &#945;-MafA and &#945;-Pax6 antibodies to the &#946;TC3 nuclear extract binding reactions. <italic>E</italic>, &#946;TC3 cells were transfected with wild-type and MafA (TGCmt) or Pax6 (CACmt) binding site mutant versions of B2 in huAII:pTK. The activity of the pTK vector is also shown. Significantly, huAII:pTK activity was only compromised in the MafA binding mutant (<italic>n</italic> = 8&#8211;11; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> huAII:pTK).</p>
###xml 9 1473 9 1456 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27"><bold>MafA stimulates B2-mediated activity, but not Pax6.</bold><italic>A</italic>, shown is the relationship of the TGC and CAC mutations to the large Maf consensus. The mutated nucleotides are <italic>underlined. B</italic>, competition assays (10&#8211;100-fold excess) were performed to analyze for MafA and Pax6 binding to the TGC and CAC mutants of B2. The TGCmt specifically competes for Pax6 binding in&#946;TC3 nuclear extracts, while only MafA binding is lost with the CACmt. <italic>C</italic>, nuclear extracts from MafB-transfected Hela cells were used in competition assays (10&#8211;100-fold excess) to analyze for MafB binding to the TGC and CAC mutants of B2. As observed with MafA, the TGC mutation does not compete for MafB binding while the CAC mutant effectively competes for MafB. A control lane with vector-transfected Hela nuclear extract is included to demonstrate the MafB-DNA complex band. <italic>D</italic>, binding assays were conducted with wild-type and mutant B2 probes to further illustrate the difference in TGCmt and CACmt binding to Pax6 and MafA, respectively. The location of MafA and Pax6 complexes were illustrated by addition of &#945;-MafA and &#945;-Pax6 antibodies to the &#946;TC3 nuclear extract binding reactions. <italic>E</italic>, &#946;TC3 cells were transfected with wild-type and MafA (TGCmt) or Pax6 (CACmt) binding site mutant versions of B2 in huAII:pTK. The activity of the pTK vector is also shown. Significantly, huAII:pTK activity was only compromised in the MafA binding mutant (<italic>n</italic> = 8&#8211;11; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> huAII:pTK).</p></caption>
###xml 1473 1473 1456 1456 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570002"/>
###xml 0 1473 0 1456 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="27"><bold>MafA stimulates B2-mediated activity, but not Pax6.</bold><italic>A</italic>, shown is the relationship of the TGC and CAC mutations to the large Maf consensus. The mutated nucleotides are <italic>underlined. B</italic>, competition assays (10&#8211;100-fold excess) were performed to analyze for MafA and Pax6 binding to the TGC and CAC mutants of B2. The TGCmt specifically competes for Pax6 binding in&#946;TC3 nuclear extracts, while only MafA binding is lost with the CACmt. <italic>C</italic>, nuclear extracts from MafB-transfected Hela cells were used in competition assays (10&#8211;100-fold excess) to analyze for MafB binding to the TGC and CAC mutants of B2. As observed with MafA, the TGC mutation does not compete for MafB binding while the CAC mutant effectively competes for MafB. A control lane with vector-transfected Hela nuclear extract is included to demonstrate the MafB-DNA complex band. <italic>D</italic>, binding assays were conducted with wild-type and mutant B2 probes to further illustrate the difference in TGCmt and CACmt binding to Pax6 and MafA, respectively. The location of MafA and Pax6 complexes were illustrated by addition of &#945;-MafA and &#945;-Pax6 antibodies to the &#946;TC3 nuclear extract binding reactions. <italic>E</italic>, &#946;TC3 cells were transfected with wild-type and MafA (TGCmt) or Pax6 (CACmt) binding site mutant versions of B2 in huAII:pTK. The activity of the pTK vector is also shown. Significantly, huAII:pTK activity was only compromised in the MafA binding mutant (<italic>n</italic> = 8&#8211;11; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> huAII:pTK).</p></caption><graphic xlink:href="zbc0340845570002"/></fig>
FIGURE 2.MafA stimulates B2-mediated activity, but not Pax6.A, shown is the relationship of the TGC and CAC mutations to the large Maf consensus. The mutated nucleotides are underlined. B, competition assays (10-100-fold excess) were performed to analyze for MafA and Pax6 binding to the TGC and CAC mutants of B2. The TGCmt specifically competes for Pax6 binding inbetaTC3 nuclear extracts, while only MafA binding is lost with the CACmt. C, nuclear extracts from MafB-transfected Hela cells were used in competition assays (10-100-fold excess) to analyze for MafB binding to the TGC and CAC mutants of B2. As observed with MafA, the TGC mutation does not compete for MafB binding while the CAC mutant effectively competes for MafB. A control lane with vector-transfected Hela nuclear extract is included to demonstrate the MafB-DNA complex band. D, binding assays were conducted with wild-type and mutant B2 probes to further illustrate the difference in TGCmt and CACmt binding to Pax6 and MafA, respectively. The location of MafA and Pax6 complexes were illustrated by addition of alpha-MafA and alpha-Pax6 antibodies to the betaTC3 nuclear extract binding reactions. E, betaTC3 cells were transfected with wild-type and MafA (TGCmt) or Pax6 (CACmt) binding site mutant versions of B2 in huAII:pTK. The activity of the pTK vector is also shown. Significantly, huAII:pTK activity was only compromised in the MafA binding mutant (n = 8-11; *, p < 0.005 versus huAII:pTK).
###end p 26
###begin p 27
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA stimulates B2-mediated activity, but not Pax6.</bold>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 165 178 165 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined. B</italic>
###xml 431 432 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 839 840 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1163 1164 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1423 1424 1406 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1433 1434 1416 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1436 1437 1419 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1446 1452 1429 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
MafA stimulates B2-mediated activity, but not Pax6.A, shown is the relationship of the TGC and CAC mutations to the large Maf consensus. The mutated nucleotides are underlined. B, competition assays (10-100-fold excess) were performed to analyze for MafA and Pax6 binding to the TGC and CAC mutants of B2. The TGCmt specifically competes for Pax6 binding inbetaTC3 nuclear extracts, while only MafA binding is lost with the CACmt. C, nuclear extracts from MafB-transfected Hela cells were used in competition assays (10-100-fold excess) to analyze for MafB binding to the TGC and CAC mutants of B2. As observed with MafA, the TGC mutation does not compete for MafB binding while the CAC mutant effectively competes for MafB. A control lane with vector-transfected Hela nuclear extract is included to demonstrate the MafB-DNA complex band. D, binding assays were conducted with wild-type and mutant B2 probes to further illustrate the difference in TGCmt and CACmt binding to Pax6 and MafA, respectively. The location of MafA and Pax6 complexes were illustrated by addition of alpha-MafA and alpha-Pax6 antibodies to the betaTC3 nuclear extract binding reactions. E, betaTC3 cells were transfected with wild-type and MafA (TGCmt) or Pax6 (CACmt) binding site mutant versions of B2 in huAII:pTK. The activity of the pTK vector is also shown. Significantly, huAII:pTK activity was only compromised in the MafA binding mutant (n = 8-11; *, p < 0.005 versus huAII:pTK).
###end p 27
###begin p 28
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 76 9 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and MafB activate through the Area II large Maf binding sites.</bold>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 315 316 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 348 9 348 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><bold>MafA and MafB activate through the Area II large Maf binding sites.</bold> MafA or MafB were cotransfected into KNRK cells with pTK, PstBst:pTK, or AII mutant versions of PstBst:pTK. Preventing large Maf binding within B2 or B4/5 significantly reduced the ability of MafA or MafB to activate PstBst:pTK (<italic>n</italic> = 4&#8211;6; <sup>*</sup>, <italic>p</italic> &lt; 0.0001 <italic>versus</italic> PstBst:pTK).</p>
###xml 9 348 9 348 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><bold>MafA and MafB activate through the Area II large Maf binding sites.</bold> MafA or MafB were cotransfected into KNRK cells with pTK, PstBst:pTK, or AII mutant versions of PstBst:pTK. Preventing large Maf binding within B2 or B4/5 significantly reduced the ability of MafA or MafB to activate PstBst:pTK (<italic>n</italic> = 4&#8211;6; <sup>*</sup>, <italic>p</italic> &lt; 0.0001 <italic>versus</italic> PstBst:pTK).</p></caption>
###xml 348 348 348 348 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570003"/>
###xml 0 348 0 348 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="29"><bold>MafA and MafB activate through the Area II large Maf binding sites.</bold> MafA or MafB were cotransfected into KNRK cells with pTK, PstBst:pTK, or AII mutant versions of PstBst:pTK. Preventing large Maf binding within B2 or B4/5 significantly reduced the ability of MafA or MafB to activate PstBst:pTK (<italic>n</italic> = 4&#8211;6; <sup>*</sup>, <italic>p</italic> &lt; 0.0001 <italic>versus</italic> PstBst:pTK).</p></caption><graphic xlink:href="zbc0340845570003"/></fig>
FIGURE 3.MafA and MafB activate through the Area II large Maf binding sites. MafA or MafB were cotransfected into KNRK cells with pTK, PstBst:pTK, or AII mutant versions of PstBst:pTK. Preventing large Maf binding within B2 or B4/5 significantly reduced the ability of MafA or MafB to activate PstBst:pTK (n = 4-6; *, p < 0.0001 versus PstBst:pTK).
###end p 28
###begin p 29
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and MafB activate through the Area II large Maf binding sites.</bold>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 309 310 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
MafA and MafB activate through the Area II large Maf binding sites. MafA or MafB were cotransfected into KNRK cells with pTK, PstBst:pTK, or AII mutant versions of PstBst:pTK. Preventing large Maf binding within B2 or B4/5 significantly reduced the ability of MafA or MafB to activate PstBst:pTK (n = 4-6; *, p < 0.0001 versus PstBst:pTK).
###end p 29
###begin p 30
###xml 85 86 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 91 92 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 149 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 151 153 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 469 475 460 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
Although normal islet beta cells and islet beta cell lines only produce MafA, insulin+/Pdx1+ progenitors express MafA and MafB during development (34, 35). To directly test the ability of MafA and MafB to stimulate AII-directed activity, each was coexpressed with an AI/AII-spanning (PstBst) reporter in the non-beta KNRK cell line. PstBst:pTK reporter activity alone is minimal in these cells (data not shown), but significantly stimulated by MafA or MafB expression (Fig. 3). Activation by these factors was compromised upon preventing large Maf binding at either B2 or B4/5. Collectively, these experiments strongly suggest that MafA and MafB, but not Pax6, stimulate AII B2 activity.
###end p 30
###begin p 31
###xml 0 69 0 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The Large Maf Binding Sites of the Pdx1 Gene Are Clustered within AII</italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 397 401 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 560 565 557 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 639 640 636 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 633 640 630 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 700 705 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
The Large Maf Binding Sites of the Pdx1 Gene Are Clustered within AII-Many Pdx1 transcription factors influence more than one control region. For example, FoxA2 acts on AIV ((12), AII (11), and AI (11), while Pdx1 and Nkx2.2 both function through AIV (12) and AI (11, 15). ChIP analysis was performed in betaTC3 cells to determine the relative distribution of MafA binding sites between conserved Pdx1 transcriptional control regions. Real-time PCR analysis was used to quantitatively compare the enrichment of these regions to that of a non-transcribed gene, PEPCK. AII sequences were highly enriched relative to AI, AIII, and AIV (Fig. 4A). Although the AI and AIII signals were slightly above the PEPCK control, this was not significant and likely represents randomly sheared chromosomal DNA (primarily 100-500 bp) encompassing AI/AII or AII/III. As expected from their close proximity, AIII, located only 45 bp from AII, had a higher signal than AI, which is separated by 300 bp.
###end p 31
###begin p 32
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 94 103 94 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Engrailed</italic>
###xml 309 311 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 483 484 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 477 484 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
To further assess functional regulation by MafA and MafB through the Pdx1 control regions, an Engrailed (En) repressor domain and MafB DNA binding domain chimera (EnMafB) was cotransfected with AI-, AII-, and AIV-driven reporters in betaTC3 cells. (The inactivity of AIII-driven reporters in beta cell lines (11) precluded analysis.) EnMafB was expected to compete with endogenous MafA and repress transcription. As predicted, EnMafB significantly reduced AII-driven activity (Fig. 4B), while not affecting AI- or AIV-mediated expression. This and the ChIP data are complementary and indicate that large Maf factors bind to and regulate specifically through Area II.
###end p 32
###begin p 33
###xml 0 64 0 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2 and B4/5 Are the Principal Large Maf Binding Sites within AII</italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 485 486 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 479 486 476 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 612 613 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 606 613 603 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 935 936 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 929 936 926 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1096 1098 1090 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mt</italic>
###xml 1136 1137 1130 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1130 1137 1124 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 1201 1202 1195 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1195 1202 1189 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
B2 and B4/5 Are the Principal Large Maf Binding Sites within AII-Because large Maf binding was localized to the AII control domain of the Pdx1 gene, we screened for additional large Maf binding elements within this region using a comprehensive series of overlapping oligonucleotides in gel shift competition assays. AI competitors served as negative controls in these experiments, and, as expected, did not significantly influence MafA binding to B2 in betaTC3 nuclear extracts (Fig. 5A). However, 3 different AII competitors did impact MafA binding, with the -2124 competitor containing both B2 and B4/5 (Fig. 5B). In contrast, the -2196 competitor spanned sequences located 5' to the highly conserved AII domain, while the conserved B12-15 elements were in -2029. Neither the -2196 nor -2029 competitors had high sequence identify with the large Maf consensus, although mutating their common TGC motif eliminated MafA binding (Fig. 5C). Preventing MafA binding in the -2196 or -2029 sequences did not further compromise B2 and B4/5 mutant activity in betaTC3 cells (see the 5' and B13 mutants (mt) in B2 + B4mt mAI/II:pTK mt of Fig. 6A), nor did EnMafB suppress B2 + B4mt mAI/II:pTK activity (Fig. 6B). These results suggest that MafA and/or MafB stimulation of AII in developing and adult beta cells is primarily through B2 and B4/5 element binding.
###end p 33
###begin p 34
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafA and MafB Bind to AII during</italic>
###xml 37 54 34 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Cell Development</italic>
###xml 217 218 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 220 221 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 351 357 345 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 409 413 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 429 434 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 542 546 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
MafA and MafB Bind to AII during beta-Cell Development-High Pdx1 levels demarcate beta cell progenitors from other exocrine and endocrine cell populations during the second and principal wave of islet cell expansion (1, 2). As a consequence, ChIP studies were performed to determine whether MafA and/or MafB bound to AII in wild-type E18.5 pancreata (Fig. 7). Anti-MafA and -MafB antibodies precipitated this Pdx1 region but not PEPCK, a gene not expressed in the pancreas. This analysis supports a direct role of these large Maf proteins in Pdx1 transcription during beta-cell maturation.
###end p 34
###begin p 35
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 9 79 9 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AII contains the only large Maf control elements within the <italic>Pdx1</italic> gene.</bold>
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 256 261 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 329 333 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 406 407 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 414 415 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 588 589 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 597 598 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 600 601 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 611 617 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 645 9 637 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><bold>AII contains the only large Maf control elements within the <italic>Pdx1</italic> gene.</bold><italic>A</italic>, formaldehyde cross-linked chromatin from &#946;TC3 cells was incubated with antibodies specific to MafA and the precipitate quantitatively analyzed for AI, AII, AIII, AIV, and <italic>PEPCK</italic> sequences by Real-time PCR. AII was highly enriched over the other <italic>Pdx1</italic> control regions. The signals were normalize to the inactive PEPCK gene (<italic>n</italic> = 4). <italic>B</italic>, &#946;TC3 cells were cotransfected with the EnMafB repressor chimera and pTK, mAI:pTK, mAII:pTK, or mAIV:pTK. EnMafB inhibited mAII-mediated activity, but not Area I or IV (<italic>n</italic> = 4&#8211;5; <sup>*</sup>, <italic>p</italic> &#8804; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p>
###xml 9 645 9 637 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><bold>AII contains the only large Maf control elements within the <italic>Pdx1</italic> gene.</bold><italic>A</italic>, formaldehyde cross-linked chromatin from &#946;TC3 cells was incubated with antibodies specific to MafA and the precipitate quantitatively analyzed for AI, AII, AIII, AIV, and <italic>PEPCK</italic> sequences by Real-time PCR. AII was highly enriched over the other <italic>Pdx1</italic> control regions. The signals were normalize to the inactive PEPCK gene (<italic>n</italic> = 4). <italic>B</italic>, &#946;TC3 cells were cotransfected with the EnMafB repressor chimera and pTK, mAI:pTK, mAII:pTK, or mAIV:pTK. EnMafB inhibited mAII-mediated activity, but not Area I or IV (<italic>n</italic> = 4&#8211;5; <sup>*</sup>, <italic>p</italic> &#8804; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p></caption>
###xml 645 645 637 637 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570004"/>
###xml 0 645 0 637 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="36"><bold>AII contains the only large Maf control elements within the <italic>Pdx1</italic> gene.</bold><italic>A</italic>, formaldehyde cross-linked chromatin from &#946;TC3 cells was incubated with antibodies specific to MafA and the precipitate quantitatively analyzed for AI, AII, AIII, AIV, and <italic>PEPCK</italic> sequences by Real-time PCR. AII was highly enriched over the other <italic>Pdx1</italic> control regions. The signals were normalize to the inactive PEPCK gene (<italic>n</italic> = 4). <italic>B</italic>, &#946;TC3 cells were cotransfected with the EnMafB repressor chimera and pTK, mAI:pTK, mAII:pTK, or mAIV:pTK. EnMafB inhibited mAII-mediated activity, but not Area I or IV (<italic>n</italic> = 4&#8211;5; <sup>*</sup>, <italic>p</italic> &#8804; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p></caption><graphic xlink:href="zbc0340845570004"/></fig>
FIGURE 4.AII contains the only large Maf control elements within the Pdx1 gene.A, formaldehyde cross-linked chromatin from betaTC3 cells was incubated with antibodies specific to MafA and the precipitate quantitatively analyzed for AI, AII, AIII, AIV, and PEPCK sequences by Real-time PCR. AII was highly enriched over the other Pdx1 control regions. The signals were normalize to the inactive PEPCK gene (n = 4). B, betaTC3 cells were cotransfected with the EnMafB repressor chimera and pTK, mAI:pTK, mAII:pTK, or mAIV:pTK. EnMafB inhibited mAII-mediated activity, but not Area I or IV (n = 4-5; *, p </= 0.01 versus each pTK reporter + pcDNA).
###end p 35
###begin p 36
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AII contains the only large Maf control elements within the <italic>Pdx1</italic> gene.</bold>
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 247 252 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 320 324 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 397 398 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 405 406 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 579 580 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 588 589 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 591 592 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 602 608 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
AII contains the only large Maf control elements within the Pdx1 gene.A, formaldehyde cross-linked chromatin from betaTC3 cells was incubated with antibodies specific to MafA and the precipitate quantitatively analyzed for AI, AII, AIII, AIV, and PEPCK sequences by Real-time PCR. AII was highly enriched over the other Pdx1 control regions. The signals were normalize to the inactive PEPCK gene (n = 4). B, betaTC3 cells were cotransfected with the EnMafB repressor chimera and pTK, mAI:pTK, mAII:pTK, or mAIV:pTK. EnMafB inhibited mAII-mediated activity, but not Area I or IV (n = 4-5; *, p </= 0.01 versus each pTK reporter + pcDNA).
###end p 36
###begin p 37
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 61 9 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AII contains three distinct large Maf binding sites.</bold>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 253 254 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 396 398 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 484 486 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 489 490 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 9 786 9 780 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><bold>AII contains three distinct large Maf binding sites.</bold><italic>A</italic>, competitor oligonucleotides (40&#8211;50 bp) spanning mouse AI and AII were used in mB2 probe gel shift binding assays in &#946;TC3 nuclear extract. The competitors are labeled by their 5&#8242;-end bp. <italic>B</italic>, wild type and mutant versions of the three AII MafA competitors are shown. Denoted is also the location of their conserved sequence blocks (<xref ref-type="bibr" rid="ref17">17</xref>), with one block labeled by the transcription factor associated with control, FoxA2 (<xref ref-type="bibr" rid="ref16">16</xref>). <italic>C</italic>, the loss of MafA binding in the -2196, -2124, and -2029 mutants is illustrated in mB2 gel shift assays performed with a 100-fold molar excess of unlabeled wild-type or mutant competitor in &#946;TC3 nuclear extract. The MafA antibody addition demonstrates the location of this protein/B2 complex.</p>
###xml 9 786 9 780 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><bold>AII contains three distinct large Maf binding sites.</bold><italic>A</italic>, competitor oligonucleotides (40&#8211;50 bp) spanning mouse AI and AII were used in mB2 probe gel shift binding assays in &#946;TC3 nuclear extract. The competitors are labeled by their 5&#8242;-end bp. <italic>B</italic>, wild type and mutant versions of the three AII MafA competitors are shown. Denoted is also the location of their conserved sequence blocks (<xref ref-type="bibr" rid="ref17">17</xref>), with one block labeled by the transcription factor associated with control, FoxA2 (<xref ref-type="bibr" rid="ref16">16</xref>). <italic>C</italic>, the loss of MafA binding in the -2196, -2124, and -2029 mutants is illustrated in mB2 gel shift assays performed with a 100-fold molar excess of unlabeled wild-type or mutant competitor in &#946;TC3 nuclear extract. The MafA antibody addition demonstrates the location of this protein/B2 complex.</p></caption>
###xml 786 786 780 780 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570005"/>
###xml 0 786 0 780 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="38"><bold>AII contains three distinct large Maf binding sites.</bold><italic>A</italic>, competitor oligonucleotides (40&#8211;50 bp) spanning mouse AI and AII were used in mB2 probe gel shift binding assays in &#946;TC3 nuclear extract. The competitors are labeled by their 5&#8242;-end bp. <italic>B</italic>, wild type and mutant versions of the three AII MafA competitors are shown. Denoted is also the location of their conserved sequence blocks (<xref ref-type="bibr" rid="ref17">17</xref>), with one block labeled by the transcription factor associated with control, FoxA2 (<xref ref-type="bibr" rid="ref16">16</xref>). <italic>C</italic>, the loss of MafA binding in the -2196, -2124, and -2029 mutants is illustrated in mB2 gel shift assays performed with a 100-fold molar excess of unlabeled wild-type or mutant competitor in &#946;TC3 nuclear extract. The MafA antibody addition demonstrates the location of this protein/B2 complex.</p></caption><graphic xlink:href="zbc0340845570005"/></fig>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
FIGURE 5.AII contains three distinct large Maf binding sites.A, competitor oligonucleotides (40-50 bp) spanning mouse AI and AII were used in mB2 probe gel shift binding assays in betaTC3 nuclear extract. The competitors are labeled by their 5'-end bp. B, wild type and mutant versions of the three AII MafA competitors are shown. Denoted is also the location of their conserved sequence blocks (17), with one block labeled by the transcription factor associated with control, FoxA2 (16). C, the loss of MafA binding in the -2196, -2124, and -2029 mutants is illustrated in mB2 gel shift assays performed with a 100-fold molar excess of unlabeled wild-type or mutant competitor in betaTC3 nuclear extract. The MafA antibody addition demonstrates the location of this protein/B2 complex.
###end p 37
###begin p 38
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AII contains three distinct large Maf binding sites.</bold>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 244 245 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 475 477 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 480 481 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
AII contains three distinct large Maf binding sites.A, competitor oligonucleotides (40-50 bp) spanning mouse AI and AII were used in mB2 probe gel shift binding assays in betaTC3 nuclear extract. The competitors are labeled by their 5'-end bp. B, wild type and mutant versions of the three AII MafA competitors are shown. Denoted is also the location of their conserved sequence blocks (17), with one block labeled by the transcription factor associated with control, FoxA2 (16). C, the loss of MafA binding in the -2196, -2124, and -2029 mutants is illustrated in mB2 gel shift assays performed with a 100-fold molar excess of unlabeled wild-type or mutant competitor in betaTC3 nuclear extract. The MafA antibody addition demonstrates the location of this protein/B2 complex.
###end p 38
###begin p 39
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 75 9 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B2 and B4/5 represent the only functional large Maf binding sites.</bold>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 245 246 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 256 257 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 259 260 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 269 275 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 285 286 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 455 456 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 464 465 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 473 479 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 507 9 501 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><bold>B2 and B4/5 represent the only functional large Maf binding sites.</bold><italic>A</italic>, &#946;TC3 cells were transfected with pTK, mAI/II:pTK, and AII TGC mutant versions of mAI/II:pTK. The 5&#8242; and/or B13 mutants do not impact B2+ B4 mt mAI/II:pTK activity (<italic>n</italic> = 13&#8211;21; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> mAI/II). <italic>B</italic>, EnMafB (or pcDNA) was cotransfected into &#946;TC3 cells with pTK, mAI/II:pTK, or B2 + B4mt mAI/II:pTK. Notably, repression by EnMafB is eliminated in the B2 and B4 mt (<italic>n</italic> = 4&#8211;8; <italic>p</italic> &lt; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p>
###xml 9 507 9 501 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><bold>B2 and B4/5 represent the only functional large Maf binding sites.</bold><italic>A</italic>, &#946;TC3 cells were transfected with pTK, mAI/II:pTK, and AII TGC mutant versions of mAI/II:pTK. The 5&#8242; and/or B13 mutants do not impact B2+ B4 mt mAI/II:pTK activity (<italic>n</italic> = 13&#8211;21; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> mAI/II). <italic>B</italic>, EnMafB (or pcDNA) was cotransfected into &#946;TC3 cells with pTK, mAI/II:pTK, or B2 + B4mt mAI/II:pTK. Notably, repression by EnMafB is eliminated in the B2 and B4 mt (<italic>n</italic> = 4&#8211;8; <italic>p</italic> &lt; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p></caption>
###xml 507 507 501 501 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570006"/>
###xml 0 507 0 501 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="40"><bold>B2 and B4/5 represent the only functional large Maf binding sites.</bold><italic>A</italic>, &#946;TC3 cells were transfected with pTK, mAI/II:pTK, and AII TGC mutant versions of mAI/II:pTK. The 5&#8242; and/or B13 mutants do not impact B2+ B4 mt mAI/II:pTK activity (<italic>n</italic> = 13&#8211;21; <sup>*</sup>, <italic>p</italic> &lt; 0.005 <italic>versus</italic> mAI/II). <italic>B</italic>, EnMafB (or pcDNA) was cotransfected into &#946;TC3 cells with pTK, mAI/II:pTK, or B2 + B4mt mAI/II:pTK. Notably, repression by EnMafB is eliminated in the B2 and B4 mt (<italic>n</italic> = 4&#8211;8; <italic>p</italic> &lt; 0.01 <italic>versus</italic> each pTK reporter + pcDNA).</p></caption><graphic xlink:href="zbc0340845570006"/></fig>
FIGURE 6.B2 and B4/5 represent the only functional large Maf binding sites.A, betaTC3 cells were transfected with pTK, mAI/II:pTK, and AII TGC mutant versions of mAI/II:pTK. The 5' and/or B13 mutants do not impact B2+ B4 mt mAI/II:pTK activity (n = 13-21; *, p < 0.005 versus mAI/II). B, EnMafB (or pcDNA) was cotransfected into betaTC3 cells with pTK, mAI/II:pTK, or B2 + B4mt mAI/II:pTK. Notably, repression by EnMafB is eliminated in the B2 and B4 mt (n = 4-8; p < 0.01 versus each pTK reporter + pcDNA).
###end p 39
###begin p 40
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B2 and B4/5 represent the only functional large Maf binding sites.</bold>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 236 237 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 247 248 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 250 251 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 260 266 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 276 277 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 446 447 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 455 456 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 464 470 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
B2 and B4/5 represent the only functional large Maf binding sites.A, betaTC3 cells were transfected with pTK, mAI/II:pTK, and AII TGC mutant versions of mAI/II:pTK. The 5' and/or B13 mutants do not impact B2+ B4 mt mAI/II:pTK activity (n = 13-21; *, p < 0.005 versus mAI/II). B, EnMafB (or pcDNA) was cotransfected into betaTC3 cells with pTK, mAI/II:pTK, or B2 + B4mt mAI/II:pTK. Notably, repression by EnMafB is eliminated in the B2 and B4 mt (n = 4-8; p < 0.01 versus each pTK reporter + pcDNA).
###end p 40
###begin p 41
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 9 73 9 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and MafB bind to <italic>Pdx1</italic> AII in developing pancreata at E18.5.</bold>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 9 419 9 419 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>MafA and MafB bind to <italic>Pdx1</italic> AII in developing pancreata at E18.5.</bold> ChIP analysis was performed on E18.5 pancreata treated with anti-MafA and -MafB antibodies. The precipitated chromatin was analyzed by PCR for <italic>Pdx1</italic> AII and <italic>PEPCK</italic> control region sequences. As controls, PCR reactions were run with input chromatin (1:200 dilution), DNA obtained after treatment with rabbit IgG, and reactions with no chromatin DNA.</p>
###xml 9 419 9 419 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>MafA and MafB bind to <italic>Pdx1</italic> AII in developing pancreata at E18.5.</bold> ChIP analysis was performed on E18.5 pancreata treated with anti-MafA and -MafB antibodies. The precipitated chromatin was analyzed by PCR for <italic>Pdx1</italic> AII and <italic>PEPCK</italic> control region sequences. As controls, PCR reactions were run with input chromatin (1:200 dilution), DNA obtained after treatment with rabbit IgG, and reactions with no chromatin DNA.</p></caption>
###xml 419 419 419 419 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570007"/>
###xml 0 419 0 419 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="42"><bold>MafA and MafB bind to <italic>Pdx1</italic> AII in developing pancreata at E18.5.</bold> ChIP analysis was performed on E18.5 pancreata treated with anti-MafA and -MafB antibodies. The precipitated chromatin was analyzed by PCR for <italic>Pdx1</italic> AII and <italic>PEPCK</italic> control region sequences. As controls, PCR reactions were run with input chromatin (1:200 dilution), DNA obtained after treatment with rabbit IgG, and reactions with no chromatin DNA.</p></caption><graphic xlink:href="zbc0340845570007"/></fig>
###xml 371 377 <span type="species:ncbi:9986">rabbit</span>
FIGURE 7.MafA and MafB bind to Pdx1 AII in developing pancreata at E18.5. ChIP analysis was performed on E18.5 pancreata treated with anti-MafA and -MafB antibodies. The precipitated chromatin was analyzed by PCR for Pdx1 AII and PEPCK control region sequences. As controls, PCR reactions were run with input chromatin (1:200 dilution), DNA obtained after treatment with rabbit IgG, and reactions with no chromatin DNA.
###end p 41
###begin p 42
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafA and MafB bind to <italic>Pdx1</italic> AII in developing pancreata at E18.5.</bold>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 362 368 <span type="species:ncbi:9986">rabbit</span>
MafA and MafB bind to Pdx1 AII in developing pancreata at E18.5. ChIP analysis was performed on E18.5 pancreata treated with anti-MafA and -MafB antibodies. The precipitated chromatin was analyzed by PCR for Pdx1 AII and PEPCK control region sequences. As controls, PCR reactions were run with input chromatin (1:200 dilution), DNA obtained after treatment with rabbit IgG, and reactions with no chromatin DNA.
###end p 42
###begin p 43
###xml 0 57 0 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB Regulates AI/II-mediated Transgene Expression during</italic>
###xml 62 79 59 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Cell Development</italic>
###xml 103 107 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 107 110 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 155 156 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 324 326 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 381 385 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 450 454 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 506 510 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafA</italic>
###xml 510 513 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 539 541 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
MafB Regulates AI/II-mediated Transgene Expression during beta-Cell Development-A notable phenotype of MafB-/- mice is the reduction in second wave insulin+ cell production from E13.5. Interestingly, although Pdx1 is detected in E15.5 hormone-negative endocrine progenitors, it is no longer present in these cells by E18.5 (20), suggesting that MafB is required for maintenance of Pdx1 transcription late in beta-cell formation. In contrast, neither Pdx1 expression nor islet cell formation is impacted in MafA-/- mice during development (45).
###end p 43
###begin p 44
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 89 94 89 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 85 94 85 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 245 250 245 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 241 250 241 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 354 355 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 379 383 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 383 386 378 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 393 399 388 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 477 479 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 542 543 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 553 557 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 557 560 549 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 580 581 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 574 581 566 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>B</italic></xref>
###xml 651 653 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 714 715 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 720 721 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 731 735 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 735 738 727 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 755 757 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 764 769 756 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 760 769 752 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 770 774 762 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 831 832 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 851 857 841 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 980 981 970 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1015 1020 1005 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 1011 1025 1001 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 1117 1121 1107 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
To examine in vivo whether MafB regulates AII-mediated transcription, we crossed the Pdx1AI/II-LacZ reporter transgenic mouse line (15) into a MafB-/- background. LacZ expression was compared in wild-type and MafB-null littermates at E18.5. Pdx1AI/II-LacZ expression is primarily restricted to the beta-cell population and labels 89 +/- 3% of the insulin+ cells in wild-type and MafB+/- mice (Fig. 8), a transgene penetrance level comparable to that in adult islet beta cells (15). In addition, transgene activity was only detected in insulin+ cells in MafB-/- littermates (Fig. 8B), recapitulating the pattern of endogenous expression in the mutant (20). However, while Pdx1 was present in essentially all insulin+/MafA+ cells in MafB-/- mice (89%, Ref. 20), Pdx1AI/II-LacZ expression was observed in a smaller fraction of insulin+ cells (19 +/- 9%, Fig. 8 and supplemental Fig. S1). Presumably, activator(s) and/or coactivator(s) levels are not sufficient in most mutant insulin+ cells to allow comprehensive Pdx1AI/II-LacZ activity. Notably, these data support a direct role for MafB in AII-directed activation of Pdx1 transcription in the developing beta-cell population.
###end p 44
###begin title 45
DISCUSSION
###end title 45
###begin p 46
###xml 293 297 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 452 456 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 558 562 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 575 577 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 624 626 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 694 698 682 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 877 881 862 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1128 1132 1110 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 1159 1161 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 1200 1202 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 1203 1205 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 1238 1240 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 1242 1244 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 1291 1293 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
Pdx1 is essential for pancreas development and adult beta-cell function. It is expressed broadly and dynamically within the developing foregut, but then is most abundantly produced in beta cells late in development and in adulthood. The factors controlling the unique transcription pattern of Pdx1 are largely unknown, but will likely be independently linked to organ specification, endocrine/exocrine cell differentiation, and beta-cell function. The Pdx1 AII control domain represents the core regulator of beta-cell-enriched expression, as concluded from Pdx1 transgenic (17) and endogenous AI-II-III knock-out analysis (13) in mice. Our results demonstrate that large Maf proteins activate Pdx1 transcription by binding to AII and illustrate how expression is compromised in developing beta cells in the specific absence of MafB. This work also supports MafA regulation of Pdx1, with a prominent role presumably in the adult islet beta-cell. The control mechanisms described here are likely to be generally utilized by large Maf transcription factors, each of which have been implicated in multiple developmental processes (e.g. (NRL), eye rod formation (36); c-Maf, chondrocyte differentiation (37-39): MafB, hindbrain segmentation (40, 41), and podocyte differentiation in the kidney (42)).
###end p 46
###begin p 47
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 400 406 400 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 593 594 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 587 594 584 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 597 605 594 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 761 767 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 833 837 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1004 1011 998 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
AII was determined to be the exclusive large Maf binding region within the Pdx1 5'-flanking region in quantitative ChIP and Pdx1-driven transfection experiments. A new AII large Maf control element, B2, was also discovered that lies directly upstream of the previously characterized B4/5 site (18). Two other potential binding sites were revealed in Area II by gel shift analysis (termed 5' and B13, Fig. 5), but activation appears to principally be through B2 and B4/5 elements, as revealed in experiments performed with the EnMafB suppressor and 5' and B13 mutants in beta cell lines (Fig. 6B). In vitro binding assays also recognized the ability of B2 to bind the Pax6 activator, albeit weakly. Specific B2 mutations that differentially eliminated large Maf versus Pax6 binding demonstrated that only large Maf proteins stimulate Pdx1 transcription in beta cell lines. Although the Pax6 interaction is weak and no detectable effect on activity was observed, it is conceivable that Pax6 could function in vivo under certain circumstances to potentiate or even competitively limit large Maf-mediated regulation.
###end p 47
###begin p 48
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">1</xref>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2</xref>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">3</xref>
###xml 362 364 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 448 449 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 461 462 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 491 495 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 530 532 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 534 536 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 798 802 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 802 805 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 856 857 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 871 872 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 942 944 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 992 993 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1043 1044 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1056 1057 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1085 1089 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 1089 1092 1070 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1143 1144 1124 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1161 1163 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 1170 1175 1151 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 1166 1175 1147 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 1176 1180 1157 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 1231 1232 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1242 1246 1223 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 1246 1249 1227 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1265 1271 1246 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1438 1442 1416 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1510 1515 1488 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 1506 1515 1484 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 1516 1520 1494 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 1524 1528 1502 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 1528 1531 1506 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1608 1609 1583 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">7</xref>
###xml 1614 1615 1589 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">8</xref>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
###xml 1093 1097 <span type="species:ncbi:10090">mice</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
MafA and MafB exhibit very similar properties in B2 and B4/5 binding and transcription-based reporter assays (Figs. 1, 2, 3). However, these factors have distinct expression patterns during beta-cell development. Hence, MafA is only detected in the beta cells produced during the massive wave of alpha- and beta-cell differentiation that starts at around E13.5 (21), termed the "secondary" transition. In contrast, MafB is produced in both glucagon+ and insulin+ cells during the "primary" (i.e. <E13) and "secondary" transition (34, 35). The developmental expression pattern of MafA is unique in relation to all other islet-enriched transcription factors, at first suggesting a critical part in inducing high Pdx1 levels in beta-cell progenitors. However, beta-cell formation was just impacted in MafB-/- mice, resulting in a specific reduction in insulin+ (and glucagon+) cell numbers without changing the overall level of endocrine cells (20). Strikingly, MafA was only detected in insulin+ cells while high Pdx1 levels were in both insulin+ and hormone- progenitors until E15.5 in MafB-/- mice, although Pdx1 was clearly reduced in hormone- cells by E18.5 (20). Pdx1AI/II-LacZ activity was also specifically detected in insulin+ cells in MafB-/- mice at E18.5 (Fig. 8). Significantly, these results demonstrated that MafB is necessary for sustaining high Pdx1 levels during beta-cell maturation. The observed occupancy of MafB within Pdx1 AII in the developing pancreas and the compromised activity of Pdx1AI/II-LacZ in MafB-/- mice supports a direct activation mechanism in developing beta cells (Figs. 7 and 8).
###end p 48
###begin p 49
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 8.</label>
###xml 9 90 9 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafB regulates AI/II-mediated transgenic expression during &#946;-cell development.</bold>
###xml 99 104 96 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 95 109 92 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 143 147 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 147 150 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 168 172 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 188 193 185 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 184 198 181 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 199 203 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 203 204 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 204 205 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">/</sup>
###xml 204 205 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>/</sup></italic>
###xml 205 206 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 214 219 211 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 206 224 203 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 225 229 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 229 232 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 247 252 244 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 243 257 240 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 259 263 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 263 266 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 315 319 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 331 334 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 347 352 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 377 378 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 384 388 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 395 396 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 439 445 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 462 463 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 468 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 541 542 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 598 599 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 616 617 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 698 9 684 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50"><bold>MafB regulates AI/II-mediated transgenic expression during &#946;-cell development.</bold> The <italic>Pdx1<sup>AI/II</sup>-LacZ</italic> transgenic line was crossed with <italic>MafB</italic><sup>+/-</sup> mice to generate <italic>MafB</italic> wild-type (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+</sup><italic><sup>/</sup></italic><sup>+</sup><italic>and Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+/-</sup>) or null (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>; <italic>MafB</italic><sup>-/-</sup>) littermates. Representative images of&#946;-gal (<italic>blue</italic>), insulin (<italic>red</italic>), and Pdx1 (<italic>green</italic>) staining in wild type (<italic>A</italic>) and <italic>MafB</italic>-null (<italic>B</italic>) transgenic pancreata at E18.5 are shown. <italic>Arrows</italic> indicate insulin<sup>+</sup>Pdx1<sup>+</sup> cells that do not produce detectable &#946;-gal. The percentage of insulin<sup>+</sup> cells (&#177;S.E.) costaining with &#946;-gal in wild type (<italic>C</italic>) and MafB-null (<italic>D</italic>) was quantitated across multiple random sections of three independent pancreata.</p>
###xml 9 698 9 684 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50"><bold>MafB regulates AI/II-mediated transgenic expression during &#946;-cell development.</bold> The <italic>Pdx1<sup>AI/II</sup>-LacZ</italic> transgenic line was crossed with <italic>MafB</italic><sup>+/-</sup> mice to generate <italic>MafB</italic> wild-type (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+</sup><italic><sup>/</sup></italic><sup>+</sup><italic>and Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+/-</sup>) or null (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>; <italic>MafB</italic><sup>-/-</sup>) littermates. Representative images of&#946;-gal (<italic>blue</italic>), insulin (<italic>red</italic>), and Pdx1 (<italic>green</italic>) staining in wild type (<italic>A</italic>) and <italic>MafB</italic>-null (<italic>B</italic>) transgenic pancreata at E18.5 are shown. <italic>Arrows</italic> indicate insulin<sup>+</sup>Pdx1<sup>+</sup> cells that do not produce detectable &#946;-gal. The percentage of insulin<sup>+</sup> cells (&#177;S.E.) costaining with &#946;-gal in wild type (<italic>C</italic>) and MafB-null (<italic>D</italic>) was quantitated across multiple random sections of three independent pancreata.</p></caption>
###xml 698 698 684 684 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0340845570008"/>
###xml 0 698 0 684 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig8"><label>FIGURE 8.</label><caption><p textid="50"><bold>MafB regulates AI/II-mediated transgenic expression during &#946;-cell development.</bold> The <italic>Pdx1<sup>AI/II</sup>-LacZ</italic> transgenic line was crossed with <italic>MafB</italic><sup>+/-</sup> mice to generate <italic>MafB</italic> wild-type (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+</sup><italic><sup>/</sup></italic><sup>+</sup><italic>and Pdx1<sup>AI/II</sup>-LacZ</italic>;<italic>MafB</italic><sup>+/-</sup>) or null (<italic>Pdx1<sup>AI/II</sup>-LacZ</italic>; <italic>MafB</italic><sup>-/-</sup>) littermates. Representative images of&#946;-gal (<italic>blue</italic>), insulin (<italic>red</italic>), and Pdx1 (<italic>green</italic>) staining in wild type (<italic>A</italic>) and <italic>MafB</italic>-null (<italic>B</italic>) transgenic pancreata at E18.5 are shown. <italic>Arrows</italic> indicate insulin<sup>+</sup>Pdx1<sup>+</sup> cells that do not produce detectable &#946;-gal. The percentage of insulin<sup>+</sup> cells (&#177;S.E.) costaining with &#946;-gal in wild type (<italic>C</italic>) and MafB-null (<italic>D</italic>) was quantitated across multiple random sections of three independent pancreata.</p></caption><graphic xlink:href="zbc0340845570008"/></fig>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
FIGURE 8.MafB regulates AI/II-mediated transgenic expression during beta-cell development. The Pdx1AI/II-LacZ transgenic line was crossed with MafB+/- mice to generate MafB wild-type (Pdx1AI/II-LacZ;MafB+/+and Pdx1AI/II-LacZ;MafB+/-) or null (Pdx1AI/II-LacZ; MafB-/-) littermates. Representative images ofbeta-gal (blue), insulin (red), and Pdx1 (green) staining in wild type (A) and MafB-null (B) transgenic pancreata at E18.5 are shown. Arrows indicate insulin+Pdx1+ cells that do not produce detectable beta-gal. The percentage of insulin+ cells (+/-S.E.) costaining with beta-gal in wild type (C) and MafB-null (D) was quantitated across multiple random sections of three independent pancreata.
###end p 49
###begin p 50
###xml 0 81 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MafB regulates AI/II-mediated transgenic expression during &#946;-cell development.</bold>
###xml 90 95 87 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 86 100 83 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 134 138 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 138 141 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 159 163 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 179 184 176 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 175 189 172 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 190 194 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 194 195 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 195 196 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">/</sup>
###xml 195 196 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>/</sup></italic>
###xml 196 197 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 205 210 202 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 197 215 194 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 216 220 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 220 223 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 238 243 235 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 234 248 231 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup>-LacZ</italic>
###xml 250 254 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 254 257 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 306 310 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 322 325 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 338 343 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 368 369 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 375 379 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 386 387 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 430 436 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 453 454 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 458 459 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 532 533 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 589 590 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 607 608 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
MafB regulates AI/II-mediated transgenic expression during beta-cell development. The Pdx1AI/II-LacZ transgenic line was crossed with MafB+/- mice to generate MafB wild-type (Pdx1AI/II-LacZ;MafB+/+and Pdx1AI/II-LacZ;MafB+/-) or null (Pdx1AI/II-LacZ; MafB-/-) littermates. Representative images ofbeta-gal (blue), insulin (red), and Pdx1 (green) staining in wild type (A) and MafB-null (B) transgenic pancreata at E18.5 are shown. Arrows indicate insulin+Pdx1+ cells that do not produce detectable beta-gal. The percentage of insulin+ cells (+/-S.E.) costaining with beta-gal in wild type (C) and MafB-null (D) was quantitated across multiple random sections of three independent pancreata.
###end p 50
###begin p 51
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 215 217 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 249 254 246 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AI/II</sup>
###xml 245 254 242 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1<sup>AI/II</sup></italic>
###xml 255 259 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 284 288 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 288 291 285 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 299 300 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 437 441 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 529 534 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 816 820 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MafB</italic>
###xml 820 823 817 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 831 832 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 840 842 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 843 845 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 1029 1030 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1038 1039 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 1085 1089 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 1148 1153 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
The signals necessary for initiating and sustaining high Pdx1 in beta-cell progenitors are found within AI/AII, as a transgene driven by these regions alone is exclusively expressed during the secondary transition (15). Notably, the presence of Pdx1AI/II-LacZ activity exclusively in MafB-/- insulin+ cells recapitulated the pattern of the endogenous gene. However, the relatively poor penetrance of the transgene relative to endogenous Pdx1 in the mutant cell population likely reflects heterogeneity in expression of other key trans-acting factors. It is unclear whether this results from differential distribution of a novel transcriptional activator(s) or, perhaps even a co-regulator(s). For example, the kinases that regulate the steady-state level and activity of MafA may not be uniformly distributed within MafB-/- insulin+ cells (43-45), even though the activator is found throughout. Similar regulatory processes may also explain why the GLUT2 transporter is only found in a comparably small fraction of mutant insulin+ cells (2). The comprehensive expression of endogenous Pdx1 in these mutant cells presumably reflects compensation by trans-regulators acting on non-AI/AII control sequences, possibly AIII or AIV.
###end p 51
###begin p 52
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 263 265 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 324 328 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 401 405 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 538 542 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 620 624 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
###xml 782 784 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 929 933 923 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx1</italic>
Collectively, our results demonstrate that AII alone contains the large Maf control elements necessary for (at least) MafB-mediated activation of Pdx1 transcription in developing beta cells. As MafA is the only other family member expressed in mature beta cells (21), this transcription factor is expected to be critical to Pdx1 expression in adults. Interestingly, AII is found only within mammalian Pdx1 genes, implying that regulation by factors like the large Mafs may be related to specific differences in the timing and/or level of Pdx1 expression in non-mammalian species. For example, differential expression of Pdx1 may impact formation of the two kinds of islets uniquely described in the avian pancreas, which contain different proportions of glucagon and insulin cells (46). Future efforts focused on identifying AII regulatory factors will provide additional insight into the novel mechanisms involved in regulating Pdx1 transcription and pancreas development in mammals, and significantly, will likely also help to identify heritable defects that cause insulin deficiency and diabetes.
###end p 52
###begin title 53
Supplementary Material
###end title 53
###begin title 54
[Supplemental Data]
###end title 54
###begin p 55
###xml 90 94 <span type="species:ncbi:9925">goat</span>
We thank Dr. C. V. E. Wright for critically reading this manuscript and for providing the goat alpha-Pdx1 antibody. Min Guo provided technical support very valuable to many of these studies.
###end p 55
###begin p 56
The abbreviations used are: Pdx, pancreatic-duodenal homeobox factor; ChIP, chromatin immunoprecipitation assay; EMSA, electrophoretic mobility shift assay; beta-gal, beta-galactosidase.
###end p 56

